ABL1 is a proto-oncogene well known as part of the fusion gene BCR-ABL1 in the Philadelphia chromosome of leukemia cancer cells 1 . Inherited germline ABL1 changes have not been associated with genetic disorders. Here we report ABL1 germline variants cosegregating with an autosomal dominant disorder characterized by congenital heart disease, skeletal abnormalities, and failure to thrive. The variant c.734A>G (p.Tyr245Cys) was found to occur de novo or cosegregate with disease in five individuals (families 1-3). Additionally, a de novo c.1066G>A (p.Ala356Thr) variant was identified in a sixth individual (family 4). We overexpressed the mutant constructs in HEK 293T cells and observed increased tyrosine phosphorylation, suggesting increased ABL1 kinase activities associated with both the p.Tyr245Cys and p.Ala356Thr substitutions. Our clinical and experimental findings, together with previously reported teratogenic effects of selective BCR-ABL inhibitors in humans [2] [3] [4] [5] and developmental defects in Abl1 knockout mice 6, 7 , suggest that ABL1 has an important role during organismal development.
Somatic and, more rarely, germline variants leading to activation or misexpression of proto-oncogenes have long been identified as important cancer drivers. Given the many important functions of proto-oncogenes, it is not surprising that germline variants in these genes can also cause human developmental disorders [8] [9] [10] [11] [12] .
We identified germline variants in ABL1 by exome sequencing and Sanger sequencing in six affected individuals who shared similar clinical features, including dysmorphic facial features (6/6), congenital heart disease (CHD; 6/6), skeletal abnormalities (6/6), joint problems (5/6), failure to thrive (5/6), gastrointestinal problems (5/6), and male genital/sexual abnormalities (3/4) (Supplementary Table 1 and Supplementary Note). In younger children, dysmorphic features included a broad forehead, small nose, deep-set eyes, and small chin. In older individuals, the face appeared elongated, with a narrow maxilla, long and narrow nose, and pointed chin (Fig. 1a) . Common skeletal abnormalities included pectus excavatum, scoliosis, finger/toe deformities, in particular hindfoot deformity, and finger contractures (Fig. 1b) . The CHD observed included atrial and ventricular septal defects and, in older individuals, aortic root dilation. Three patients had joint hyperextensibility/laxity. Most individuals had failure to thrive during infancy and early childhood (Supplementary Fig. 1 ). Hypospadias/hypogonadism was reported in three of four male patients. On the basis of cardiac and skeletal manifestations, differential diagnoses commonly included connective tissue disorders, for example, Marfan syndrome in family 3.
Clinical exome sequencing was performed on the four probands, as previously described (Supplementary Table 2 ) 13, 14 . Exome sequencing and Sanger fill-in of regions poorly covered by exome sequencing did not identify any causal variants in known disease-relevant genes (Supplementary Tables 3 and 4) . Instead, all probands were found to carry novel heterozygous nonsynonymous variants in ABL1 (NM_007313.2, isoform 1b). One variant, c.734A>G (p.Tyr245Cys), was recurrent in families 1-3, while the other variant, c.1066G>A (p.Ala356Thr), was heterozygous in a single proband from family 4 (Figs. 2 and 3, Table 1 and Supplementary Fig. 2 ). Sanger sequencing of the asymptomatic parents of the probands in families 1 and 2 was negative for p.Tyr245Cys, indicating that the variant arose de novo in the probands. The similarly affected daughter of subject 1 was found to have inherited the heterozygous p.Tyr245Cys substitution. In family 3, p.Tyr245Cys was found to be inherited 6 1 4 VOLUME 49 | NUMBER 4 | APRIL 2017 Nature GeNetics l e t t e r s from the similarly affected father. In family 4, p.Ala356Thr was found to be de novo in the proband.
Unlike many recurrent variants that occur at CpG dinucleotides, the recurrent c.734A>G variant is not located within a CpG site. This variant has been detected in four unrelated but similarly affected individuals (three probands in this report and a fourth individual who was not included owing to lack of consent) from approximately 6,900 consecutive and unrelated individuals referred for clinical exome sequencing. There is significant enrichment of this variant in our affected patient cohort as compared to 0/60,700 in the database from the Exome Aggregation Consortium (ExAC; accessed July 2016; P = 3 × 10 −9 , χ 2 test; Supplementary Data 1).
ABL1 has two isoforms, 1a (NM_005157.5) and 1b (NM_007313.2), as a result of an alternatively spliced first exon. Isoform 1b has 19 additional N-terminal residues that are absent in isoform 1a; myristoylation of these residues has a role in autoinhibition of the kinase activity. The two missense variants in our patients are expected to affect both isoforms. Residues Tyr245 and Ala356 in isoform 1b correspond to Tyr226 and Ala337 in isoform 1a, respectively.
To investigate the potential effects of the two ABL1 variants, we transiently transfected HEK 293T cells with plasmid constructs encoding C-terminally tagged wild-type and mutant proteins using cDNA for both human ABL1 isoforms (Fig. 4 and Supplementary Figs. 3-5 ).
Endogenous levels of overall phosphotyrosine (p-Tyr) and phosphorylation of specific ABL1 substrates (STAT5) were measured by immunoblotting. Overexpression of the mutant constructs for both isoforms resulted in increased overall phosphotyrosine levels and increased phosphorylation of specific ABL1 substrates (STAT5) when compared to cells expressing wild-type protein ( Fig. 4 and Supplementary  Fig. 5 ). These results indicate that both the c.734A>G (p.Tyr245Cys) and c.1066G>A (p.Ala356Thr) variants cause increased phosphorylation, suggesting increased ABL1 kinase activity.
Of note, Tyr245 and Ala356 are both known as key residues regulating ABL1 kinase activity. The Tyr245 residue is one of the two tyrosine residues required for autophosphorylation-induced activation of ABL1 intrinsic kinase activity. It was shown that, while autophosphorylation causes an 18-fold increase in the activity of wild-type ABL1, introduction of p.Tyr245Phe, which affects the same residue as p.Tyr245Cys in families 1-3, results in inhibition of such activation by 50% (ref. 15) . This is in contrast to the increased phosphorylation associated with the p.Tyr245Cys substitution found in this study. To exclude the possibility of systematic differences between our experimental settings and those reported previously 15 , we overexpressed the reported mutant construct. Consistent with the previous report, we observed decreased overall phosphotyrosine for Tyr245Phe when compared to the wildtype protein for both isoforms (Supplementary Figs. 6 and 7) . These results support the contention that the p.Tyr245Phe and p.Tyr245Cys substitutions have opposite effects (gain of function versus loss of function) on ABL1 kinase activities.
The Ala356 residue is located in the myristoyl-binding site of the ABL1 kinase domain, which intramolecularly binds the N-terminal myristoyl group and forms an autoinhibitory conformation. It was shown that p.Ala356Asn, which affects the same amino acid as p.Ala356Thr identified in family 4, resulted in higher kinase activity than that seen for wild-type protein 16 . Our findings on the Ala356Thr mutant suggest that these two changes affecting Ala356, that is, to asparagine versus threonine, have similar effects. Of note, residue Ala356 in isoform 1b is located in the binding site for the N-terminal myristoyl group, which is unique to isoform 1b. However, our data showed that the substitution of this residue in isoform 1a, p.Ala337Thr, also caused increased phosphorylation (Supplementary Fig. 5 ).
To test whether mutant ABL1 transcript is expressed in the affected individuals, we conducted semiquantitative RT-PCR on lymphoblastderived cell lines from affected subjects 1 and 2 (F1:II1 and F1:III1) and an unaffected control (F1:II2) (cell lines from other individuals not available). Sanger sequencing of the RT-PCR products showed . Note long face with narrow maxilla and pointed chin in subjects 1 and 3. Younger individuals (subjects 2 and 6) manifest broad forehead, deep-set eyes, small nose, and small chin. (b) Skeletal abnormalities. From left to right: subjects 1, 2, 3, and 6. Abnormalities include pectus excavatum, scoliosis, hindfoot deformity causing pes planus, and finger contractures. Informed consent was obtained from subject 1 and from the parents/legal guardians of subjects 2, 3, and 6 to publish these photographs. l e t t e r s approximate 1:1 ratios of wild-type and mutant ABL1 alleles (Supplementary Fig. 8 ), indicating similar levels of ABL1 expression in affected and control individuals.
Mouse models suggest an important role of ABL1 during development. Abl1 knockout mice have growth delay, cardiac hyperplasia, and osteoporosis 6, 7 . We reevaluated the ventricular wall thickness of our patients and confirmed that there is no cardiac hyperplasia (data not shown). This may be due to the fact that the variants identified in this study lead to increased phosphorylation while the mice have Abl1 null alleles. Overexpression of wild-type Abl1, but not kinase-defective Abl1, can rescue the mutant phenotypes of Abl1 knockout mice, suggesting that ABL1 kinase activity is essential for normal development 17 .
Intriguingly, severe congenital malformations have been reported in fetuses exposed to imatinib, a selective tyrosine kinase inhibitor that inhibits BCR-ABL, c-KIT, and PDGFRA, used in the treatment of multiple cancers, most notably Philadelphia chromosome (BCR-ABL)-positive CML, raising concern for potential teratogenic effects of the drug 2-5 . Pye et al. studied a cohort of 180 women exposed to imatinib during pregnancy and identified 12 fetuses with abnormalities, mostly exposed to the drug during the first trimester 2 . Anomalies of the 12 fetuses included scoliosis/vertebral defects (3), CHD (2), hypospadias (2), and pyloric stenosis (1) 2, 3 . On the basis of the small number of cases, no definitive conclusions about the potential teratogenicity of imatinib can be drawn, especially as some of the cases were also exposed to additional teratogens, such as Coumadin/warfarin or hydroxyurea. Others have also reported potential teratogenic effects of imatinib, including CHD, skeletal anomalies, hypospadias, intestinal malrotation, and imperforate anus 4, 5 . This spectrum of phenotypes overlaps with what was found in our patients, including scoliosis (3/6), CHD (6/6), hypospadias/hypogonadism (3/4), pyloric muscle thickening (1/6), and imperforate anus (1/6). These similarities between fetuses exposed to imatinib during pregnancy and human patients with constitutional ABL1 variants, along with the studies in mice, suggest that ABL1 function needs to be tightly regulated during development and that dysregulation can cause congenital malformations.
Our data suggest a novel genetic syndrome caused by constitutional ABL1 variants, which affects growth and the cardiovascular and skeletal systems. The differential diagnosis of the newly described syndrome includes Shprintzen-Goldberg syndrome (dolichostenomelia, arachnodactyly, pectus deformity, scoliosis, aortic root enlargement, and high-arched palate) and Loeys-Dietz syndrome (long face, high-arched palate, microretrognathia, pectus deformity, scoliosis, arachnodactyly, joint laxity, and aortic root aneurysm with risk of dissection). Given the evidence of increased transforming growth The Tyr245 residue is located in the linker region between the SH2 and kinase domains, while the Ala356 residue is located in the kinase domain (prepared on the basis of UniProt database domains, P00519). (c) 3D structure of the ABL1 1b protein isoform, its N-terminal domains, and the location of the two mutated ABL1 residues (based on structural data from Nagar et al. 18 (PDB 1OPL) using Swiss-PdbViewer 19 ). Alanine-to-asparagine substitution at the same Ala356 residue leads to higher ABL1 kinase activity 16 The two variants are absent in the dbSNP, ESP, ExAC, and COSMIC databases. NGS, next-generation sequencing.
a The GenBank transcript ID used for the nucleotide and amino acid changes in isoform 1b was NM_007313.2.
l e t t e r s factor (TGF)-β signaling associated with connective tissue disorders, we investigated whether ABL1 variants affect TGF-β signaling by measuring the phosphorylation level of SMAD2 and SMAD3. In the context of our experimental settings, we did not observe significant alteration in the phosphorylation level of SMAD2 and SMAD3 (Fig. 4 and Supplementary Figs. 4 and 5) .
Malignancies have not been detected in any of the affected individuals with germline ABL1 variants, but, as these variants cause increased phosphorylation and possibly increased kinase activity of this proto-oncogene, it may be prudent to perform systematic clinical screening for ABL1-associated cancers in the newly identified individuals.
In conclusion, we report that germline variants in ABL1 cause a syndrome characterized by CHD, skeletal abnormalities, and failure to thrive. ABL1 joins the growing list of genes that are implicated in both cancer and human developmental disorders. Data were normalized to GAPDH protein levels, with the wild-type protein set at 1.0. **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001; n.s., P > 0.05, one-way ANOVA with Tukey's multiple-comparisons test.
URLs

